Beam Therapeutics Inc.
BEAM
$15.47
$0.845.74%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -90.49% | -17.01% | -41.48% | -69.39% | 1,478.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -90.49% | -17.01% | -41.48% | -69.39% | 1,478.04% |
| Cost of Revenue | -27.58% | -5.79% | -10.83% | -14.88% | 62.24% |
| Gross Profit | -140.53% | 3.46% | 2.87% | -2.61% | 365.62% |
| SG&A Expenses | -33.74% | 4.35% | 20.16% | 13.77% | 90.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.03% | -3.74% | -4.58% | -9.42% | 68.16% |
| Operating Income | -175.30% | 1.63% | -2.69% | -5.26% | 249.30% |
| Income Before Tax | -162.67% | -0.60% | -9.95% | -2.29% | 485.99% |
| Income Tax Expenses | -100.00% | -- | -- | -- | 36.60% |
| Earnings from Continuing Operations | -163.27% | -0.60% | -10.00% | -2.29% | 472.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -163.27% | -0.60% | -10.00% | -2.29% | 472.36% |
| EBIT | -175.30% | 1.63% | -2.69% | -5.26% | 249.30% |
| EBITDA | -168.44% | 1.99% | -2.04% | -4.69% | 262.53% |
| EPS Basic | -161.77% | 3.53% | -2.01% | 9.51% | 425.95% |
| Normalized Basic EPS | -160.91% | 0.19% | 13.25% | -1.01% | 259.73% |
| EPS Diluted | -163.44% | 3.53% | -2.01% | 9.51% | 418.29% |
| Normalized Diluted EPS | -162.31% | 0.19% | 13.25% | -1.01% | 256.16% |
| Average Basic Shares Outstanding | 2.43% | 4.28% | 7.83% | 13.04% | 14.24% |
| Average Diluted Shares Outstanding | 0.15% | 4.28% | 7.83% | 13.04% | 16.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
